Thu Feb 20, 2014 7:46am EST
(Reuters) – Raptor Pharmaceutical Corp said its experimental brain disorder drug slowed the loss of muscle control in patients with Huntington’s disease after 18 months of treatment.
Raptor’s shares were up 9 percent at $16.24 in premarket trading on Thursday.
The drug slowed the progression of muscle spasms, eye and hand movements and loss of balance compared to a placebo.
The trial enrolled 96 patients with Huntington’s disease, a genetic disorder caused by the degeneration of nerve cells in parts of the brain, resulting in the loss of executive function and uncontrollable movements.
The company said seven patients discontinued treatment during the study. Six of them were treated with the drug, codenamed RP103.
Raptor is also testing the drug in a mid-stage study for non-alcoholic fatty liver disease in children.